Wall Street Zen Upgrades Janux Therapeutics (NASDAQ:JANX) to “Hold”

Janux Therapeutics (NASDAQ:JANX) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Sunday.

JANX has been the topic of several other reports. Barclays decreased their price target on shares of Janux Therapeutics from $48.00 to $29.00 and set an “overweight” rating on the stock in a research note on Wednesday, December 17th. Cantor Fitzgerald decreased their price target on shares of Janux Therapeutics from $150.00 to $100.00 and set an “overweight” rating on the stock in a research note on Friday, February 27th. Guggenheim decreased their price target on shares of Janux Therapeutics from $72.00 to $68.00 and set a “buy” rating on the stock in a research note on Friday, February 27th. Piper Sandler decreased their price target on shares of Janux Therapeutics from $42.00 to $30.00 and set an “overweight” rating on the stock in a research note on Friday, January 16th. Finally, Clear Str downgraded shares of Janux Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 20th. Eleven research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Janux Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $56.91.

Janux Therapeutics Stock Performance

JANX stock opened at $14.94 on Friday. The company has a market capitalization of $908.83 million, a PE ratio of -8.16 and a beta of 2.82. Janux Therapeutics has a one year low of $12.12 and a one year high of $35.34. The company’s 50 day moving average price is $13.71 and its two-hundred day moving average price is $18.85.

Janux Therapeutics (NASDAQ:JANX) last posted its quarterly earnings results on Thursday, February 26th. The company reported ($0.51) EPS for the quarter, topping the consensus estimate of ($0.65) by $0.14. The business had revenue of $7.88 million for the quarter, compared to analysts’ expectations of $0.08 million. On average, research analysts predict that Janux Therapeutics will post -1.38 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. Janus Henderson Group PLC increased its stake in shares of Janux Therapeutics by 13.8% in the fourth quarter. Janus Henderson Group PLC now owns 5,350,453 shares of the company’s stock worth $73,850,000 after buying an additional 649,341 shares during the period. State Street Corp increased its stake in shares of Janux Therapeutics by 103.8% in the fourth quarter. State Street Corp now owns 3,853,951 shares of the company’s stock worth $53,185,000 after buying an additional 1,962,486 shares during the period. Vanguard Group Inc. increased its stake in shares of Janux Therapeutics by 10.4% in the third quarter. Vanguard Group Inc. now owns 2,417,104 shares of the company’s stock worth $59,074,000 after buying an additional 227,676 shares during the period. Prosight Management LP increased its stake in shares of Janux Therapeutics by 176.5% in the fourth quarter. Prosight Management LP now owns 2,392,523 shares of the company’s stock worth $33,017,000 after buying an additional 1,527,173 shares during the period. Finally, Orbimed Advisors LLC increased its stake in shares of Janux Therapeutics by 10.7% in the fourth quarter. Orbimed Advisors LLC now owns 1,954,426 shares of the company’s stock worth $26,971,000 after buying an additional 188,326 shares during the period. 75.39% of the stock is owned by hedge funds and other institutional investors.

Janux Therapeutics Company Profile

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.